From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia
Andreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, Jorge E Cortes, Timothy Hughes, Jane Apperley, Oliver Hantschel, Delphine Rea, Peter Schuld, Hagop Kantarjian · 2026
Read From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia by Andreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, Jorge E Cortes, Timothy Hughes, Jane Apperley, Oliver Hantschel, Delphine Rea, Peter Schuld, Hagop Kantarjian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13233626.txt.
Description
Andreas Hochhaus and colleagues published a 2026 review marking twenty-five years of tyrosine kinase inhibitors in chronic myeloid leukemia. The disease stems from a chromosome swap that creates the BCR::ABL1 fusion gene, whose enzyme drives uncontrolled white cell growth. Imatinib, the first drug blocking that enzyme, produced responses never seen before and quickly became standard care.
Later drug generations overcame resistance and intolerance, bringing life expectancy for responders close to that of the wider public. Goals have shifted toward quality of life and treatment-free remission, which landmark stop-treatment studies show about half of eligible patients can maintain. Remaining challenges include resistance, safety, and widening access. The authors survey newer drugs, combinations, and immune approaches that may push more patients toward functional cure.
Catalog record
| CREATOR | Andreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, Jorge E Cortes, Timothy Hughes, Jane Apperley, Oliver Hantschel, Delphine Rea, Peter Schuld, Hagop Kantarjian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |